135 related articles for article (PubMed ID: 15320594)
21. The effects of food and divided dosing on the bioavailability of oral vinorelbine.
Rowinsky EK; Lucas VS; Hsieh AL; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Donehower RC
Cancer Chemother Pharmacol; 1996; 39(1-2):9-16. PubMed ID: 8995494
[TBL] [Abstract][Full Text] [Related]
22. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
23. Phase I dose escalation of single-agent vinblastine in dogs.
Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE
J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250
[TBL] [Abstract][Full Text] [Related]
24. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
Hirsh V; Desjardins P; Needles BM; Rigas JR; Jahanzeb M; Nguyen L; Zembryki D; Leopold LH
Am J Clin Oncol; 2007 Jun; 30(3):245-51. PubMed ID: 17551300
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
26. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Aapro MS
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
[TBL] [Abstract][Full Text] [Related]
27. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.
Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Saijo N; Nishiwaki Y
Lung Cancer; 2007 Mar; 55(3):337-41. PubMed ID: 17126951
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
[TBL] [Abstract][Full Text] [Related]
30. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer.
Crawford J; O'Rourke M; Schiller JH; Spiridonidis CH; Yanovich S; Ozer H; Langleben A; Hutchins L; Koletsky A; Clamon G; Burman S; White R; Hohneker J
J Clin Oncol; 1996 Oct; 14(10):2774-84. PubMed ID: 8874339
[TBL] [Abstract][Full Text] [Related]
31. Vinorelbine (Navelbine). A new semisynthetic vinca alkaloid.
Krikorian A; Breillout F
Onkologie; 1991 Feb; 14(1):7-12. PubMed ID: 2057177
[TBL] [Abstract][Full Text] [Related]
32. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
[TBL] [Abstract][Full Text] [Related]
33. Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014).
Lenz JA; Robat CS; Stein TJ
J Small Anim Pract; 2016 Aug; 57(8):429-34. PubMed ID: 27251593
[TBL] [Abstract][Full Text] [Related]
34. Vinorelbine: a new antineoplastic drug for the treatment of non-small-cell lung cancer.
Jones SF; Burris HA
Ann Pharmacother; 1996 May; 30(5):501-6. PubMed ID: 8740332
[TBL] [Abstract][Full Text] [Related]
35. Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
Hoffman PC; Masters GA; Drinkard LC; Krauss SA; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Jun; 23(3 Suppl 6):11-5. PubMed ID: 8677441
[TBL] [Abstract][Full Text] [Related]
36. Two case reports of vinorelbine extravasation: management and review of the literature.
Cicchetti S; Jemec B; Gault DT
Tumori; 2000; 86(4):289-92. PubMed ID: 11016706
[TBL] [Abstract][Full Text] [Related]
37. A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer.
Hotta K; Sekine I; Tamura T; Sawada M; Watanabe H; Kusaba H; Akiyama Y; Inoue A; Shimoyama T; Nokihara H; Ueda Y; Yamamoto N; Kunitoh H; Ohe Y; Kodama T; Saijo N
Jpn J Clin Oncol; 2001 Dec; 31(12):596-600. PubMed ID: 11902490
[TBL] [Abstract][Full Text] [Related]
38. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
39. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
40. [The incidence of phlebitis in the patients administrated vinorelbine by intravenous bolus injection--a retrospective study].
Nakayama S; Matsubara N; Sakai T; Aso N
Gan To Kagaku Ryoho; 2002 Apr; 29(4):633-5. PubMed ID: 11977554
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
